Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 13/20 | 0.73 |
| ▸ | NPPA | P01160 | 5/20 | 0.73 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.44 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6808018 | 0.93 | MME (0.68) | MMENPPAHPGDITGB1ITGA4 | |
| SCHEMBL6808554 | 0.90 | MME (0.61) | MMENPPA | |
| SCHEMBL6807169 | 0.84 | MME (0.52) | MMENPPAITGB1ITGA4MMP1 | |
| SCHEMBL6807360 | 0.84 | MME (0.73) | MMENPPAITGB1ITGA4MMP1 | |
| SCHEMBL6807211 | 0.84 | MME (0.57) | MMENPPAHPGDITGB1ITGA4 | |
| SCHEMBL6807209 | 0.84 | MME (0.57) | MMENPPAHPGDITGB1ITGA4 | |
| SCHEMBL8331455 | 0.84 | MME (0.73) | MMENPPAITGB1ITGA4MMP1 | |
| SCHEMBL6807616 | 0.83 | MME (0.72) | MMENPPAITGB1ITGA4MMP1 | |
| SCHEMBL6255996 | 0.83 | MME (0.73) | MMENPPAITGB1ITGA4MMP1 | |
| SCHEMBL6806867 | 0.78 | MME (0.64) | MMENPPAITGB1ITGA4MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004056787-A1 | CYCLOPENTYL GLUTARAMIDES AND THEIR USE AS NEUTRAL ENDOPEPTIDASE INHIBITORS | PFIZER LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | MME 1/4885NPPA 53/4885HPGD 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.